Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Value of Body Composition Analysis in Predicting Delayed Emergence From Remimazolam-based General Anesthesia: A Prospective Observational Study.

NCT05512559 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT05512559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05512559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Value of Body Composition Analysis in Predicting Delayed Emergence From Remimazolam-based General Anesthesia: A Prospective Observational Study.
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Unknown status
Start date
September 5, 2022
Completion date
March 31, 2023
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

body composition, remimazolam